Product sales were, in millions:
Three Months Ended Sept. 30, Nine Months Ended Sept. 30,
2007 2006 Increase 2007 2006 Increase
diagnostics $51.8 $43.3 20 % $149.5 $125.8 19 %
Blood screening $45.6 $40.2 13 % $129.0 $114.0 13 %
sales $97.4 $83.5 17 % $278.5 $239.8 16 %
Collaborative research revenues in the third quarter of 2007 were $3.1 million, compared to $1.5 million in the prior year period, an increase of 107% that resulted primarily from higher reimbursement from Novartis of shared expenses in the companies' blood screening collaboration. For the first nine months of 2007, collaborative research revenues were $11.2 million, compared to $14.7 million in the prior year period, a decrease of 24% that resulted primarily from the reclassification of revenue associated with investigational use of the PROCLEIX WNV assay. Beginning in the third quarter of 2006, the Company began recording all revenue associated with this assay in product sales, rather than in collaborative research revenues. The assay was approved by the US Food and Drug Administration (FDA) for use on Gen-Probe's enhanced semi-automated instrument system (eSAS) in December of 2005, and for use on the TIGRIS system in March of 2006.
Royalty and li
|SOURCE Gen-Probe Incorporated|
Copyright©2007 PR Newswire.
All rights reserved